OBI filed application for Phase II human clinical trial of first-in-class novel prodrug, OBI-3424, to TFDA

1.Date of occurrence of the event:2023/02/02 2.New drug name or code: first-in-class novel prodrug, OBI-3424 3.Indication: OBI-3424 is converted into a potently cytotoxic DNA alkylating agent specifically by the AKR1C3 enzyme, which is expressed by a variety of tumors leading to selective killing of those cells. Potential study subjects will have their tumor cells tested […]

This article is password protected.

To view the content, please enter your password in the field below